Yi, Ming

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,445

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,145

Regulation of PD-L1 expression in the tumor microenvironment

Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 681

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer

Cancer Immunotherapy and BiomarkersAngiogenesis and VEGF in Cancer

Cited by 608

Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy

Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology

interferon and immune responsesCancer Immunotherapy and Biomarkers

Cited by 413

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

Yi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., Luo, S., Zhou, P., & Wu, K. (2021) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersTGF-β signaling in diseases

Cited by 233

The role of cancer-derived microRNAs in cancer immune escape

Yi, M., Xu, L., Jiao, Y., Luo, S., Li, A., & Wu, K. (2020) · Journal of Hematology & Oncology

MicroRNA in disease regulationCancer Immunotherapy and Biomarkers

Cited by 221

Gut microbiome modulates efficacy of immune checkpoint inhibitors

Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 179

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

Yi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 163

Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor

Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy

Cancer Immunotherapy and BiomarkersTGF-β signaling in diseases

Cited by 153

Prospects for combining immune checkpoint blockade with PARP inhibition

Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersPARP inhibition in cancer therapy

Cited by 143

Advances and perspectives of PARP inhibitors

Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology & Oncology

PARP inhibition in cancer therapyDNA Repair Mechanisms

Cited by 117

Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy

Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 69

The role of gut microbiota in immune checkpoint inhibitor therapy

Yi, M., Qin, S., Chu, Q., & Wu, K. (2018) · HepatoBiliary Surgery and Nutrition

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 32

The biology of combination immunotherapy in recurrent metastatic head and neck cancer

Yuan, X., Yi, M., Zhang, W., Xu, L., Chu, Q., Luo, S., & Wu, K. (2021) · The International Journal of Biochemistry & Cell Biology

Cancer Immunotherapy and BiomarkersHead and Neck Cancer Studies

Cited by 13